Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
TESARO, Inc. Gives Notice of Anticipated Make-Whole Adjustment Event to Holders of Its Convertible Senior Notes WALTHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that, pursuant to the terms of the indenture (the “Indenture”) governing the terms of its 3.00% Convertible Senior notes due 2021 (the “Notes”), it anticipates that a Make-Whole Adjustment Event, as such term is defined in the Indenture, will occur as a result of completion of the proposed transactions contemplated by the Agreement and Plan...
TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting Initial data from AMBER trial of TSR-022 (anti-TIM-3) in combination with TSR-042 (anti-PD-1) demonstrated clinical activity in patients who have progressed following anti-PD-1 treatmentTSR-042 monotherapy demonstrated significant activity in patients with previously treated recurrent/advanced NSCLC across all PD-L1 TPS categoriesInvestor webcast to highlight SITC data presentations and TESARO’s immuno-oncology portfolio on November 12 WASHINGTON, Nov. 09, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO),...
TESARO Announces Third-Quarter 2018 Operating Results ZEJULA® Q3 net sales totaled $63 million compared to $39 million for Q3 2017Top-line results for PRIMA trial of ZEJULA monotherapy for first-line ovarian cancer patients regardless of BRCA mutation status anticipated in late 2019Data presented at ESMO for TSR-042 indicate robust activity in patients with MSI-high endometrial cancer; TSR-042 BLA submission planned for 2H 2019 WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today reported operating results ...
The Foundation for Women’s Cancer and TESARO Partner on the Race to End Women’s Cancer for 3rd Year CHICAGO and WALTHAM, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- The Foundation for Women’s Cancer (FWC), the official foundation of the Society of Gynecologic Oncology (SGO), and TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the third year of their partnership supporting the annual National Race to End Women’s Cancer. The weekend-long event is the FWC’s pinnacle awareness and fundraising event, celebrating survivors, honoring loved ones, creating a...
TESARO Announces Achievement of ZEJULA Prostate Cancer Development Milestones by Janssen WALTHAM, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced the achievement of development milestones that trigger an $18 million payment from Janssen Biotech Inc. (Janssen). The milestones are related to Janssen’s ongoing GALAHAD trial, which is assessing niraparib monotherapy for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) and DNA-repair anomalies. Data from the trial are anticipat...
TESARO and Actress Cobie Smulders Launch Not on My Watch, a National Movement to Empower the Ovarian Cancer Community Not on My Watch Aims to Shine a Light on the Importance of an Informed, Proactive Approach to Treatment WALTHAM, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, announced today the launch of Not on My Watch, a movement to empower the ovarian cancer community, especially women with recurrent ovarian cancer, to take informed and proactive steps against the threat of another disease recurrence. Internation...
TESARO Announces Data Presentations at ESMO 2018 Congress Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancerPRIMA safety data for individualized niraparib dose regimen presentedTop-line results for PRIMA trial of niraparib in first-line ovarian cancer regardless of biomarker status expected in late 2019 MUNICH, Germany, Oct. 20, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today summarized updated Phase 1 GARNET data of TSR-042 (anti-PD-1 anti...
TESARO to Announce Third-Quarter 2018 Financial Results on November 1, 2018 WALTHAM, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO) will announce third-quarter 2018 financial results on Thursday, November 1, 2018, after the close of the U.S. financial markets. TESARO’s senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on November 1, 2018 to discuss the Company’s operating results for the quarter in greater detail, as well as the status of its development programs. This quarterly earnings call will be available via phone and...
TESARO Announces Data Presentations at the ESMO 2018 Congress WALTHAM, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that data from six abstracts will be presented at the European Society for Medical Oncology (ESMO) Congress from October 19-23, 2018 in Munich, Germany. “At this year’s ESMO Congress, blinded, pooled interim safety data from PRIMA will be presented, which demonstrated that an individualized starting dose of ZEJULA resulted in a favorable tolerability profile compared to a fixed starting ...
The independent financial analyst theScreener just allocated a lower risk rating to TESARO INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 2 out of 4 possible stars. Its market behaviour, however, has slightly improved and can be qualified as moderately risky. theScreener considers that these elements merit an overall rating upgrade to Neutral. As of the analysis date October 5, 2018, the closing price was USD 42.88 and its expected v...
TESARO Announces Data Presentations at the SITC 2018 Annual Meeting WALTHAM, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that data from a total of five abstracts will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 7-11, 2018 in Washington, D.C. “At this year’s SITC Annual Meeting, we are excited that several abstracts will be presented highlighting data from our rapidly advancing immuno-oncology portfolio, including an oral presentation of the first clinic...
TESARO Announces Participation at Two Investor Conferences WALTHAM, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are: The Cantor Global Healthcare Conference at the InterContinental New York Barclay Hotel on Wednesday, October 3, 2018. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, are scheduled to present an overview of the Company’s business and development programs at 11:30...
TESARO Announces Expansion to Second Stage of JASPER Trial of ZEJULA® in Combination With TSR-042 in Non-Small Cell Lung Cancer All evaluable patients experienced tumor shrinkageProtocol defined response criteria achieved and trial expansion ongoing WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced it has initiated the second stage of the JASPER study that is designed to assess clinical benefit of ZEJULA® in combination with an anti-PD-1 antibody in first-line non-small cell lung cancer (NSCLC) ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.